Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Speciality MedicinesBOM:544738 -6.76%21 Gross Margin % is 26.88% as of Mar. 2026, which is 4% below its 10-year median of 28.10. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 942 Drug Manufacturers companies, Speciality Medicines ranks worse than 84.39% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Speciality Medicines had a gross margin of 26.88% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Speciality Medicines Gross Margin % Related Terms
Speciality Medicines Gross Margin % Historical Data
* Premium members only.
The historical data trend for Speciality Medicines's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines Gross Margin % Chart
Speciality Medicines Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
Gross Margin %
13.36
30.79
33.87
27.63
28.10
Speciality Medicines Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
Gross Margin %
0.00
0.00
0.00
25.61
26.88
BOM:544738 vs ZTS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Speciality Medicines's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Speciality Medicines Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Speciality Medicines's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Speciality Medicines's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Speciality Medicines (BOM:544738) has a Gross Margin % of 26.88% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Speciality Medicines and its competitors. This is near median its historical median of 28.10. Over the past decade, Speciality Medicines' Gross Margin % has ranged from 13.36 to 33.87. According to the industry distribution chart, Speciality Medicines ranks #795 out of 942 companies in the Drug Manufacturers industry, placing it in the top 84.4%.
Is Speciality Medicines' Gross Margin % too high?
Speciality Medicines' current Gross Margin % of 26.88% is near median its 10-year median of 28.10. Over the past 10 years, this metric has ranged from a low of 13.36 to a high of 33.87. The Drug Manufacturers industry median Gross Margin % is 48.50. Speciality Medicines' value of 26.88% is 44.6% below this industry median. Based on the distribution chart, Speciality Medicines ranks #795 out of 942 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Speciality Medicines ranks #795 out of 942 companies for Gross Margin %. This places Speciality Medicines in the lower half of its industry. The industry median Gross Margin % is 48.50. Speciality Medicines' value of 26.88% is 44.6% below this benchmark. Historically, Speciality Medicines' own Gross Margin % has ranged from 13.36 to 33.87 over the past decade. While the company's 10-year median is 28.10 vs. the industry median of 48.50, Speciality Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Speciality Medicines's current Gross Margin % of 26.88% is 44.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Speciality Medicines and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Speciality Medicines's current Gross Margin % is 26.88%, which is near median its own 10-year median of 28.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current Gross Margin % of 26.88%. The current Gross Margin % is 26.88%, which is near median its 10-year median of 28.10 and 44.6% below the Drug Manufacturers industry median of 48.50. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current Gross Margin % is 26.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score
Get the complete analysis for BOM:544738
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544738 has been successfully added to your 
